ReviewBritish journal of cancer2020

Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.

Viktor Grünwald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.